FLIGHT ATTENDANT PATIENT EXPLAINS EXCITEMENT FOR AXIOMED VISCOELASTIC DISC REPLACEMENT
TO ORTHOPEDIC SPINE SURGEON INVENTOR DR. KINGSLEY CHIN
AxioMed is compiling its 5-year IDE Clinical study data to submit to the FDA. Target to get the disc to market in 2022 and immediately follow with an abbreviated lateral lumbar disc study.
One of the key radiographic findings is the absence of heterotopic bone commonly seen with articulating disc replacement spacers.
Advantages of AxioMed
-Allows for compression (shock absorption)
-One-piece design
-Stronger than the human disc
-Constant center of rotation = the human disc
-No recorded endplate-bonding failure in testing or clinical use
-Dynamic testing with longevity over 50 years
-No wear debris in repetitive cycling testing
Kingsley R. Chin, M.D. MBA NewGen Marketing Co
Contact us to learn about AxioMed's viscoelastic material.
[email protected]
www.AxioMed.com
www.KICVenturesGroup.com
DISCLAIMER
This post does not constitute an offer of any security.